Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: EphB4 receptor/ligand modulators - VasGene

Next Previous
Search
Drug Profile

Research programme: EphB4 receptor/ligand modulators - VasGene

Alternative Names: anti-EphB4 monoclonal antibody - VasGene; EphB4 neutralising Ab - VasGene; EphB4 neutralising antibody - VasGene; EphB4 neutralizing Ab - VasGene; EphB4 receptor tyrosine kinase inhibitor - VasGene; EphB4 RTK inhibitor - VasGene; EphB4 soluble receptor - VasGene; EphB4-131; Ephrin B2 agonist - VasGene; Vas 02; Vas 101; Vas 102; Vas 103; Vas 104; Vas 105; VasG3 MAb; VasG4 MAb; VasG5 MAb

Latest Information Update: 28 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VasGene Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors; Ephrin-B2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Cancer; Eye disorders
  • Discontinued Vascular disorders

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Parenteral)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top